Congenital Heart Disease — Predictors of Aortic Root Dilatation in Tetralogy of Fallot Patients
Citation(s)
Chong WY, Wong WH, Chiu CS, Cheung YF Aortic root dilation and aortic elastic properties in children after repair of tetralogy of Fallot. Am J Cardiol. 2006 Mar 15;97(6):905-9. doi: 10.1016/j.amjcard.2005.09.141. Epub 2006 Feb 3.
Colan SD, McElhinney DB, Crawford EC, Keane JF, Lock JE Validation and re-evaluation of a discriminant model predicting anatomic suitability for biventricular repair in neonates with aortic stenosis. J Am Coll Cardiol. 2006 May 2;47(9):1858-65. doi: 10.1016/j.jacc.2006.02.020. Epub 2006 Apr 17.
Kim W, Kwak JG, Cho S, Kim WH Ten-year follow-up of dilatation of aortic structures in Fallot-type anomalies. Pediatr Cardiol. 2023 Oct;44(7):1552-1559. doi: 10.1007/s00246-023-03225-7. Epub 2023 Jul 5.
Konstantinov IE, Fricke TA, d'Udekem Y, Robertson T Aortic dissection and rupture in adolescents after tetralogy of Fallot repair. J Thorac Cardiovasc Surg. 2010 Nov;140(5):e71-3. doi: 10.1016/j.jtcvs.2010.06.045. Epub 2010 Aug 1. No abstract available.
Niwa K, Siu SC, Webb GD, Gatzoulis MA Progressive aortic root dilatation in adults late after repair of tetralogy of Fallot. Circulation. 2002 Sep 10;106(11):1374-8. doi: 10.1161/01.cir.0000028462.88597.ad.
Niwa K Aortic root dilatation in tetralogy of Fallot long-term after repair--histology of the aorta in tetralogy of Fallot: evidence of intrinsic aortopathy. Int J Cardiol. 2005 Aug 18;103(2):117-9. doi: 10.1016/j.ijcard.2004.07.002.
Rathi VK, Doyle M, Williams RB, Yamrozik J, Shannon RP, Biederman RW Massive aortic aneurysm and dissection in repaired tetralogy of Fallot; diagnosis by cardiovascular magnetic resonance imaging. Int J Cardiol. 2005 May 11;101(1):169-70. doi: 10.1016/j.ijcard.2004.05.037. No abstract available.
Predictors of Aortic Root Dilatation in Tetralogy of Fallot Patients
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
